Acquired Resistance to Osimertinib in <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?

Acquired Resistance to Osimertinib in <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?

Osimertinib is currently the preferred first-line therapy in patients with non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (<i>EGFR</i>) mutation and the standard second-line therapy in T790M-positive patients in progression to previous EGFR tyrosine kinas...

Full description

Bibliographic Details
Main Authors: Elisa Bertoli, Elisa De Carlo, Alessandro Del Conte, Brigida Stanzione, Alberto Revelant, Kelly Fassetta, Michele Spina, Alessandra Bearz
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:International Journal of Molecular Sciences
Subjects:
osimertinib
acquired resistance
<i>EGFR</i>-mutated
NSCLC
Online Access:https://www.mdpi.com/1422-0067/23/13/6936

Internet

https://www.mdpi.com/1422-0067/23/13/6936

Similar Items